Immune cell therapy plus gemcitabine after pancreas surgery
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This Phase 3 trial tests whether adding an immune cell therapy (Immuncell-LC) to the standard chemotherapy drug gemcitabine helps people with resectable pancreatic cancer after surgery. It aims to improve safety and outcomes like preventing the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 20 to 80 years old
- Have pancreatic ductal adenocarcinoma confirmed by biopsy or cell test
- Have had surgery to remove the tumor completely or near-completely (R0 or R1), and at least 2 weeks have passed after surgery (up to 12 weeks)
- No spread to distant organs (for example liver or peritoneum); no distant metastases
- Be well enough for treatment: performance status (ECOG) 0 to 2 and life expectancy of at least 12 weeks
- Plan to start gemcitabine alone as the after-surgery (post-op) chemotherapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach that combines a special type of radiation therapy (called PRaG) with an immunotherapy drug to treat advanced pancreatic cancer that hasn't spread. The goal is to see if this combination can shrink or control the tumor and help you live longer.
This trial tests whether adding an immunotherapy drug (sintilimab) to standard chemotherapy before and after surgery helps shrink tumors and improve outcomes for people with pancreatic cancer that can be removed.
This trial tests a combination of an immunotherapy drug (adebrelimab) with chemotherapy before surgery for pancreatic cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This trial tests a new type of immunotherapy (called Lm-LLO-TT) combined with a standard chemotherapy drug (gemcitabine) for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination is safe and effective.
This study tests a new combination of two drugs for advanced pancreatic cancer. It aims to see if adding an immunotherapy drug (which helps your immune system attack cancer) to standard chemotherapy can help control the cancer better.
This trial tests a combination of a chemotherapy drug (irinotecan liposome) plus an immunotherapy drug (addebelizumab) given before surgery to people with pancreatic cancer that can be fully removed. The goal is to see if this treatment reduces the chance of the cancer coming back and improves outcomes.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.